PMID: 236810May 17, 1975Paper

Controlled study of atenolol in treatment of hypertension

British Medical Journal
L HanssonA Westerlund


The antihypertensive effect of atenolol, a new beta-1-receptor blocking agent, was studied in a double-blind trial in which 45 patients with essential hypertension were randomly assigned to placebo or atenolol treatment. Atenolol caused a statistically significant and clinically relevant reduction of blood pressure. The optimum daily dose for moderately severe hypertension was considered to be 200 mg. Several irrelevant side effects were collected by the use of a check list, but there was no difference in the number of complaints during placebo and active treatment. Atenolol has a useful antihypertensive effect and, at least theoretically, has advantages over other beta-adrenergic blocking agents.


Sep 20, 1973·The American Journal of Cardiology·P Kincaid-Smith
Jan 31, 1974·The New England Journal of Medicine·A AmeryR Fagard
May 1, 1973·British Heart Journal·P A MajidS H Taylor
Jun 29, 1974·British Medical Journal·E C Huskisson, J A Wojtulewski
Sep 19, 1964·British Medical Journal·B N Prichard, P M Gillam


Jan 31, 1979·Psychopharmacology·A A LandauerF W Prott
Jan 1, 1985·European Journal of Clinical Pharmacology·A Westerlund
Jan 1, 1977·European Journal of Clinical Pharmacology·N P Boye, J R Vale
Jan 1, 1977·European Journal of Clinical Pharmacology·D L ClementR Pannier
Mar 22, 1976·European Journal of Clinical Pharmacology·L HanssonB E Karlberg
Jan 1, 1982·European Journal of Clinical Pharmacology·D E PapadoyannisN B Karatzas
Oct 14, 1977·European Journal of Clinical Pharmacology·L HanssonM Holm
Jan 1, 1980·Pharmacology & Therapeutics·B N Prichard, C W Owens
Sep 10, 2013·Journal of Plastic, Reconstructive & Aesthetic Surgery : JPRAS·M de GraafSuzanne G M A Pasmans
Oct 1, 1977·British Journal of Clinical Pharmacology·T A JeffersN P Barker
Mar 29, 2012·Vascular Health and Risk Management·Jorge Eduardo ToblliFernando Pablo Dominici
Oct 1, 1982·European Journal of Clinical Pharmacology·H T FolgeringR H van Haaren
Sep 30, 1976·European Journal of Clinical Pharmacology·J F De PlaenT Reybrouck
Jan 1, 1977·Current Medical Research and Opinion·N K GostickN P Barmer
Jul 19, 2011·Journal of the American Academy of Dermatology·Martine F RaphaëlJohannes M P J Breur
Nov 1, 1976·Progress in Cardiovascular Diseases·M E ConollyC T Dollery
Mar 1, 1977·American Heart Journal·J C PetrieJ Webster
Jan 1, 1982·British Journal of Clinical Pharmacology·L AndrénL Hansson
Dec 1, 1996·American Heart Journal·L BienenfeldS P Glasser
Jan 1, 1976·The Journal of International Medical Research·A M HarrisJ A Tweed
Apr 19, 2018·The Cochrane Database of Systematic Reviews·Monica NovoaIngrid Arevalo-Rodriguez
May 1, 1978·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·P R ReevesM J Winrow
Apr 1, 1980·British Journal of Clinical Pharmacology·B FlouvatA Baglin
Mar 11, 2016·The Cochrane Database of Systematic Reviews·Gavin W K WongJames M Wright
Jan 1, 1985·Acta Medica Scandinavica·L AndrénL Hansson

Related Concepts

Adrenergic beta-Antagonists
Blood - Brain Barrier Anatomy
Clinical Trials
Hypertensive Disease

Related Feeds

Blood Brain Barrier Chips

The blood brain barrier (BBB) is comprised of endothelial cells that regulate the influx and outflux of plasma concentrations. Lab-on-a-chip devices allow scientists to model diseases and mechanisms such as the passage of therapeutic antibodies across the BBB. Discover the latest research on BBB chips here.

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

Blood Brain Barrier

The blood brain barrier is a border that separates blood from cerebrospinal fluid. Discover the latest search on this highly selective semipermeable membrane here.